As shown in our study, intermediate metabolizers with minor stroke or TIA had a similar efficacy with ticagrelor compared with clopidogrel, which might partly support the use of an alternative P2Y12 inhibitor not only for poor metabolizers but also for intermediate metabolizers when considering clopidogrel for neurovascular indications. This evidence concerns the gene P2RY12 and transient ischemic attack.